Standard dose of effervescent progesterone vaginal tablet for luteal phase support in frozen embryo transfer cycle
Not Applicable
Recruiting
- Conditions
- infertility
- Registration Number
- JPRN-UMIN000021983
- Lead Sponsor
- Sanno Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 400
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who had a history of oversensitivity, abnormal uterine bleeding of undetermined origin, missed abortion, ectopic pregnancy, severe hepatic disorder, breast cancer, genital cancer and porphyria, and are under breast-feeding.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ongoing pregnancy rate (six weeks after administration of the drug)
- Secondary Outcome Measures
Name Time Method 1) hCG positive rate 2) clinical pregnancy rate 3) safety information 4) withdrawal rate 5) relationship between ongoing pregnancy rate and age or serum progesterone level